(0.21%) 5 191.87 points
(0.08%) 38 883 points
(0.13%) 16 371 points
(0.24%) $78.67
(0.32%) $2.20
(-0.36%) $2 322.90
(-0.26%) $27.54
(2.40%) $988.10
(0.03%) $0.928
(0.67%) $10.90
(0.28%) $0.798
(-0.06%) $91.29
2 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 8.02%
0.05% $ 21.43
@ $11.17
Wydano: 14 vas. 2024 @ 22:35
Zwrot: 91.85%
Poprzedni sygnał: vas. 14 - 21:36
Poprzedni sygnał:
Zwrot: 1.92 %
Live Chart Being Loaded With Signals
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors...
Stats | |
---|---|
Dzisiejszy wolumen | 364 478 |
Średni wolumen | 2.07M |
Kapitalizacja rynkowa | 1.82B |
EPS | $-0.390 ( 2024-03-21 ) |
Następna data zysków | ( $-0.370 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.78 |
ATR14 | $0.00300 (0.01%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Leamon Christopher P | Buy | 106 100 | Stock Option (Right to Buy) |
2024-01-04 | Leamon Christopher P | Buy | 63 700 | Restricted Stock Units |
2023-08-31 | Leamon Christopher P | Buy | 11 957 | Common Stock |
2024-01-04 | Crowley John J | Buy | 106 100 | Stock Option (Right to Buy) |
2024-01-04 | Crowley John J | Buy | 63 700 | Restricted Stock Units |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 6 470 725 | Sell: 164 236 |
Wolumen Korelacja
Fusion Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
QADB | 0.977 |
CMPI | 0.965 |
ALBO | 0.952 |
JNCE | 0.945 |
EBACU | 0.945 |
TZPS | 0.932 |
MCAA | 0.931 |
DXPE | 0.927 |
ARTEU | 0.926 |
IVCB | 0.924 |
10 Najbardziej negatywne korelacje | |
---|---|
RGF | -0.951 |
IMRX | -0.943 |
ORPH | -0.942 |
PRTS | -0.939 |
ATAK | -0.937 |
NDLS | -0.934 |
MTEM | -0.934 |
RGC | -0.932 |
RMGC | -0.928 |
WKSP | -0.927 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Fusion Pharmaceuticals Korelacja - Waluta/Towar
Fusion Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | $2.07M |
Zysk brutto: | $723 000 (34.96 %) |
EPS: | $-1.450 |
FY | 2023 |
Przychody: | $2.07M |
Zysk brutto: | $723 000 (34.96 %) |
EPS: | $-1.450 |
FY | 2022 |
Przychody: | $1.46M |
Zysk brutto: | $-57.43M (-3 931.14 %) |
EPS: | $-2.00 |
FY | 2021 |
Przychody: | $1.44M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.884 |
Financial Reports:
No articles found.
Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej